marqzy.in

Tag: Healthcare Investing

  • Merck Q4 & Full-Year 2025 Earnings: Key Insights

     

    arnings scene showing


    Key Takeaways

    • Merck’s earnings call on 3 February 2026 at 9:00 a.m. ET will cover Q4 and full-year 2025 sales, earnings, and future outlook, with executives sharing insights on performance.
    • Analysts expect Q4 2025 EPS of $2.08 and revenue of $16.2 billion, driven by strong sales from Keytruda and other products, though challenges like supply chains may arise.
    • Merck’s 2025 sales are projected to reach $64.5-65 billion, reflecting growth in oncology and vaccines, amid global economic trends like 3.1% growth forecasted by the IMF for 2026.
    • Investors should watch for updates on Keytruda, which hit $8.1 billion in Q3 sales, and guidance for 2026, as the pharma sector faces supply issues and declining aid in low-income countries.
    • The call could impact Merck’s stock, currently trading around $105, similar to how earnings announcements have influenced peers like Pfizer.

    Introduction

    Imagine a world where one medicine saves millions of lives while driving billions in revenue for a company. That’s the story of Merck and its blockbuster drug Keytruda, a key player in cancer treatment. As we step into 2026, the pharmaceutical industry is at a crossroads. Global health spending is shifting, with the World Bank noting stagnation in low-income countries and a drop in aid, while the IMF predicts modest economic growth of 3.1% worldwide. In this landscape, Merck, a giant in healthcare, is set to reveal its financial health for 2025.

    On 3 February 2026, Merck will hold its fourth-quarter and full-year 2025 sales and earnings conference call. This event isn’t just a routine update; it’s a window into how one of the world’s leading pharma companies navigated a year of challenges and opportunities. From supply chain disruptions to breakthroughs in oncology, the call will offer insights that could shape investor decisions and market trends.

    Let’s start with why this matters. Merck, known as MSD outside the US and Canada, has been a cornerstone of healthcare for over 130 years. In 2025, the company faced a mix of headwinds and tailwinds. Global trade tensions, as highlighted in the IMF’s World Economic Outlook, affected supply chains for pharma firms. Yet, Merck’s focus on innovation helped it push forward. Their vaccine and oncology portfolios, especially Keytruda, drove growth despite these issues.

    Keytruda, an immunotherapy drug, has been a star performer. In 2025, it crossed new milestones, with Q3 sales alone reaching $8.1 billion – the first time it topped $8 billion in a quarter. This represents a 10% increase from the previous year, showing how early-stage cancer treatments are expanding their market. But with patents set to expire in 2028, investors are keen to hear about what’s next.


    The broader economy plays a role too. The Federal Reserve sees rates falling to 3.4% by late 2026, a supportive backdrop for innovation-led firms. Such as Merck. Meanwhile, the World Bank warns of declining donor aid for health in lower-middle-income countries, which could impact global sales of vaccines like Gardasil.

    This conference call comes at a pivotal time. Merck’s stock has had a volatile 2025, dropping about 5% overall but recovering from a 17% dip earlier in the year. Trading around $105 in early 2026, shares are below the 52-week high of $112.90. Analysts see growth potential, with a B Growth Style Score and expected 17.4% earnings rise.

    What can we expect? Company executives will discuss sales figures, earnings per share, and guidance for 2026. In past calls, topics like tariff impacts and pipeline updates have been hot. For instance, in Q3 2025, Merck reported $17.3 billion in revenue, up 4%, with adjusted earnings of $2.58 per share.

    To understand the excitement, think about the pharma industry’s evolution. Post-COVID, focus shifted to oncology and vaccines. Merck’s animal health division also contributed, adding diversity. The IMF notes that regulatory reforms could amplify industrial policies, benefiting firms investing in education and infrastructure – areas where Merck excels.

    Investors, from individual shareholders to institutional funds, tune in for clues on dividends, buybacks, and acquisitions. Merck’s recent moves, like acquiring Cidara Therapeutics in January 2026, show a commitment to growth. The call might touch on how this fits into their strategy.

    (more…)

  • Merck Q4 & FY2025 Earnings Call Preview

     Merck’s Upcoming Q4 and Full-Year 2025 Earnings Call: A Preview for Investors


    a laptop displaying stock charts,

    ​

    Introduction


    As we start the new year in January 2026, the pharmaceutical industry is preparing for one of its most important events. Merck & Co. (known as MSD outside the US) has officially announced that it will host its Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call on 3 February 2026. For investors, analysts, and anyone interested in healthcare, this date is marked in red on the calendar.

    ​Earnings calls are far more than just a routine financial update. They are a moment of truth where a company’s leadership explains how they navigated the last twelve months and, more importantly, what they plan to do next. For a giant like Merck, which plays a massive role in cancer treatment and global vaccines, this call will set the tone for the entire sector in 2026.

    ​1. Why the 3 February Call is So Important

    ​Imagine you are a part-owner of a global business. You would want to know if your investment is safe and growing. On 3 February 2026, at 9:00 a.m. ET, Merck’s CEO, Rob Davis, and CFO Caroline Litchfield will provide that answer.

    ​This call is vital because it covers the Full-Year 2025 results. This means we get the complete picture of how Merck handled the entire year. It’s not just about how much money they made; it’s about their strategy in a world filled with trade tensions, new medical technologies, and changing government policies. For investors, these insights are essential for making smart decisions about buying or selling shares.

    ​2. The Power of Keytruda: The Heart of Merck’s Success

    ​When discussing Merck, the conversation always starts with Keytruda. This oncology (cancer) drug is one of the most successful medicines ever created. Throughout 2025, it has remained the engine that drives Merck’s financial growth.

    ​Current Projections:

    Analysts and researchers suggest that Merck’s full-year sales for 2025 could reach between $64.1 billion and $65.6 billion.

    • ​Growth: A huge portion of this is expected to come from Keytruda sales, which have shown double-digit growth in previous quarters.
    • ​Impact: In Q4 2025 alone, earnings per share (EPS) are projected to be around $2.08. This would mark a 21% growth compared to the previous year, showing just how strong the company’s momentum is as we enter 2026.

    ​3. Understanding the Patent Cliff Challenge

    ​Even though Merck is doing very well right now, there is a dark cloud on the horizon known as the Patent Cliff. This is a term used when the legal protection (patent) for a drug expires. Once the patent ends, other companies can make cheaper versions of the drug, which causes the original company’s profits to drop.

    ​Keytruda is so successful that its eventual patent expiration is a major worry for investors. During the February call, everyone will be listening for updates on how Merck plans to handle this.

    • ​Are they developing a new version of Keytruda that lasts longer?
    • ​Do they have new drugs in the pipeline to replace the lost income?

    ​These are the billion-dollar questions that leadership must answer to keep investor confidence high.

    ​4. Global Economic Pressures: Trade and Tariffs

    ​No company exists in a bubble. Merck is heavily affected by what is happening in the world economy. As we sit here in January 2026, three major economic factors are likely to be discussed during the call:

    ​Trade Tensions and Tariffs:

    If international trade wars continue or if new tariffs are placed on imported chemicals and medicines, Merck’s costs will go up. This can eat into their profits and make medicine more expensive for everyone.

    ​Supply Chain Resilience:

    Making medicine is a complex process that involves many different countries. Any delay in shipping or a problem at a factory can cause big issues. Merck has been working hard to make its supply chain stronger, and investors will want to hear that their labs and factories are running smoothly.

    ​Inflation:

    High energy costs and rising wages also play a role. To stay profitable, Merck must find ways to be more efficient, perhaps by using more automation or smarter logistics.

    ​5. Industry Trends: AI and Strategic Acquisitions

    ​To stay ahead of the competition, Merck is investing heavily in two areas: Technology and Partnerships.

    ​Artificial Intelligence (AI) in Drug Discovery:

    One of the most exciting trends for 2026 is the use of AI. Traditionally, it takes 10 years and billions of dollars to bring a new drug to the market. Merck is now using AI to predict which medicines will work, which could save years and millions of dollars.

    ​Strategic Acquisitions:

    Merck often uses its extra cash to buy smaller, innovative biotech companies. For example, their interest in companies like Cidara Therapeutics shows they are diversifying into anti-fungals and other rare treatments. This way, they aren’t just relying on Keytruda for all their money.

    ​6. A Look at the 2025 Performance 

    ​To understand why the upcoming call is so anticipated, we can look at the steady progress Merck has made throughout the last year.

    Quarter (2025)

    Estimated Sales (Billion USD)

    Main Driver

    Q1

    ~$15.5

    High demand for Keytruda

    Q2

    ~$15.8

    Growth in vaccine sales

    Q3

    ~$16.0

    Major advances in oncology

    Q4 (Projected)

    ~$16.2

    Strong year-end performance

    7. How to Make the Most of the Earnings Call

    If you are an investor or just a student of business, here is how you can use the 3 February call to your advantage:

    Listen to the Webcast: Merck makes the call public on their website. You can hear the CEO’s tone of voice—is he confident or worried?

    Watch the Guidance: The most important part is the 2026 Outlook. If Merck predicts even more growth for next year, the stock price might rise.

    Read the Q&A: This is when expert analysts ask the tough questions. It’s often the most honest part of the whole hour.

    Frequently Asked Questions (FAQs)


    Q1. When exactly is Merck’s next earnings call?

    It is scheduled for 3 February 2026 at 9:00 a.m. ET. It will cover the results for both Q4 and the full year of 2025.

    Q2. Why is Keytruda so important for Merck?

    Keytruda is their biggest cancer treatment drug. It makes up a huge portion of their total sales, so its success is directly linked to the company’s stock price.

    Q3. What is a Patent Cliff?

    It is when a company’s legal right to be the only seller of a drug expires. This allows competition to enter the market and lower the original company’s profits.

    Q4. How does AI help a pharmaceutical company like Merck?

    AI helps Merck find new drug candidates much faster and more accurately than traditional lab work alone, saving both time and money.

    Conclusion

    As we count down the days to 3 February 2026, it is clear that Merck is in a very strong position, but they are not without challenges. While their 2025 sales have been impressive, the looming patent cliff and global trade tensions mean they must stay innovative to survive.

    By focusing on new technologies like AI and buying smart biotech companies, Merck is trying to build a future that is bigger than just one blockbuster drug. For anyone watching the markets this January, Merck’s upcoming report card will be one of the most important stories of the year.

     Disclaimer: All content on Marqzy is for educational purposes only and is not financial advice. We are not SEBI-registered advisors. Investments carry risks; please consult a professional and perform your own due diligence before investing. Marqzy is not liable for any financial losses.

  • UnitedHealth Q3 2025 Earnings: What to Expect

     
    Realistic newsroom tone


    UnitedHealth’s Big Tuesday: What’s Actually at Stake?


    ​Honestly, I’ve always reckoned that waiting for a massive company like UnitedHealth (UNH) to report its earnings is a bit like waiting for the results of a high-stakes football match. You’ve done the prep. Seen the players. But until that whistle blows on Tuesday morning… nobody really knows which way the wind is going to blow. On 28 October 2025, the eyes of the entire financial world were glued to this healthcare giant. And to be fair, they had every reason to be nervous.

    ​If you’re sitting there with your morning cuppa, wondering why a health insurance company matters to your portfolio, stay with me. UNH isn’t just a company. It’s a monster in a $5 trillion industry. When they speak, the whole market listens. Whether you’re a serious investor or just someone trying to make sense of the 2025 economy, this Q3 update was a big deal. Straight up.

    ​The Morning Rush: What Went Down

    ​Look, let’s talk about the timing first. UNH usually drops its numbers around 6:00 AM ET, way before the markets even open. By the time most people have had their first coffee, the share price is already jumping around like a toddler on a sugar rush.

    ​The big question everyone was asking: Can they beat the estimates? Analysts were looking for an Earnings Per Share (EPS) of about $2.81. Now, UNH has a bit of a reputation for over-delivering. They’ve got a history of hitting about 3% above what people expect. But in a volatile year like 2025? Nothing was a given. Not by a long shot.

    ​The Secret Weapon: Optum

    ​Straight up, the reason UnitedHealth is such a beast isn’t just because of insurance. It’s because of Optum. If UNH is the body, Optum is the brain. It’s their tech and data arm, and it’s been growing at a mental pace—about 18% year-on-year.

    ​Experts were betting that Optum would add at least $0.20 to the EPS this quarter. Why? Because they’ve gone all-in on AI. Properly speaking, we’re talking about using AI to process claims and spot errors before they happen. Recent filings suggested that AI alone saved them $1 billion so far in 2025. That’s not just “tech talk.” That’s proper money going straight back to the bottom line.

    ​The “John Deere” Lesson (Again)

    ​I know I keep coming back to this, but it’s a perfect parallel. Remember how John Deere struggled when farmers couldn’t afford a new kit? Well, UNH has its own version of that struggle. Even though they’re a giant, they aren’t bulletproof. Fact.

    ​In 2025, the big “handbrake” for healthcare companies will be cybersecurity costs and Medicare Advantage rate cuts. If the government decides to pay a bit less for healthcare, or if a massive cyberattack happens—like the one that rattled the industry recently—margins can be squeezed by 1-2% quickly.

    ​Just like Deere had to pivot to tech to survive a slump, UNH has had to pivot to “vertical integration.” Basically, they own the doctors, the data, and the insurance. It’s a shield that protects them when one part of the economy starts to wobble. It’s smart, really.

    The Big Question: Is This Stock a Buy or a Bust?

    ​To be fair, at $366 a share, UNH isn’t exactly a bargain-bin find. It’s trading at about 18x forward earnings. For a “boring” healthcare stock, that’s quite a high price tag. But then again, you aren’t just buying an insurance company. You’re buying a tech-driven cash machine with a 1.7% dividend yield.

    ​Most investors were looking to see if the company would hike its “guidance“—that’s just a fancy way of saying they think they’ll make even more money later in the year. If they did? A jump to $400 by December wasn’t out of the question. But if they missed? Well, post-earnings moves for UNH average about 4%, so you’ve got to have a stomach for a bit of a rollercoaster.

    Metric

    Estimated Value

    Why does it matter?

    Expected EPS

           $2.81

           This is the “pass or fail” mark for the quarter.

    Optum Growth

           

            18%

           

            If this dips, the “tech” story loses its magic.

    Dividend Yield

           

            1.7%

           

            The safety net for long-term “Buffett” style investors.

    Cyber Costs

           

            1-2% Margin Hit

           

            The “handbrake” that could spoil the party.

    Target Price

           

            $400

          

            The “moon shot” goal if they hike their guidance.

    ​The Human Side of the Numbers

    ​Properly speaking, we often get lost in the “billions” and the “basis points.” But UNH’s earnings actually tell us a lot about how people are living in 2025. Are people going to the doctor more? Are they spending more on expensive drugs?

    ​One big worry was the election’s impact on drug pricing. There was a lot of chatter that new laws could hike UNH’s drug spend by 10%. That’s a massive hit. It’s a reminder that even these corporate titans are at the mercy of the folks in Washington.

    ​I was chatting with a mate who works in the industry, and he put it perfectly: “UNH is like a massive tanker. It takes a lot to move it, but when it does, it creates a huge wake.” That wave is what every retail investor is trying to ride.

    ​What Should You Do Now?

    ​If you were watching this back in October 2025, or if you’re looking at it now in 2026, the strategy is basically the same:

    • ​Don’t panic on the day: Earnings days are always messy. If the stock dips 5% on Tuesday morning, it doesn’t mean the company is failing. Look at the long-term trend.
    • ​Watch Optum, not just UNH: If Optum’s growth slows down, that’s a much bigger warning sign than a small miss on the insurance side.
    • ​Check the AI stats: AI is the real growth engine here. If they’re still saving billions through automation, they’ve got a massive edge over their rivals.
    • ​Think like Buffett: Warren Buffett has held stakes in companies like this because they’re essential. People will always need doctors and insurance, no matter what the economy is doing.


    Final Thoughts

    ​Look, the UnitedHealth Q3 earnings weren’t just another boring financial update. They were a glimpse into the future of how we pay for health and how tech is taking over the world. Whether they “beat” or “busted,” the sheer scale of UNH makes it a permanent fixture in the UK and US markets.

    ​Honestly, the best thing you can do is stay informed and don’t get caught up in the 24-hour news cycle drama. Healthcare is a long game. If you’ve got the patience, UNH is usually a solid bet, but you’ve got to be ready for those “cyber-scare” bumps along the road.

    ​Stay sharp, keep an eye on those Tuesday morning numbers, and maybe—just maybe—you’ll see that $400 target hit sooner than you think.

    FAQ 

    What time does UnitedHealth report earnings on Tuesday? 

    Honestly, it’s an early start. They usually drop the numbers around 6:00 AM ET, way before the market opens. If you’re trading, you’ll need your coffee ready early for that 8:00 AM conference call.

    Will UNH beat earnings estimates this quarter? 

    Look, they’ve got a solid track record of hitting about 3% above what people expect. With Optum’s AI saving them billions, a beat is definitely on the cards, but in 2025, nothing is a dead cert.

    How does Optum affect UnitedHealth’s stock price? 

    To be fair, Optum is the real engine room. If their tech and data arm shows that 18% growth again, it could lift the whole stock, even if the insurance side is a bit flat. It’s the secret weapon.

    What are the biggest risks for UnitedHealth in 2025? 

    Straight up, it’s all about the “handbrakes.” Cybersecurity costs and government rate cuts for Medicare are the big ones. One bad cyber-scare and those margins can get squeezed properly fast.

    Note: This is for educational purposes only. Not financial advice. We are not SEBI-registered.